Our research identified new growth opportunities for pharmaceutical and biopharmaceutical companies that focus on growth driven by innovation and commercial models that are focused on patient outcomes.
|Clear evidence of continued recovery in industry performance: The industry outlook has continued to improve with Enterprise Value rising—driven by improved future growth forecasts. Entry in emerging markets and expedient product launches are still driving the markets, however, investor sentiment has shifted and science-based innovation strategies are now eclipsing diversification.|
|Some companies are breaking away from the pack through science-based innovation strategies: Our High Performance Business rankings for 2013, based on trailing 12 month Q3-2013 financials, show significant and rapid improvement in performance for a handful of companies, largely driven by recent and upcoming product launches based on scientific innovations versus diversified strategies.|
|The High Performers are putting science back into Life Sciences: The High Performers are bringing new science to the market in key areas of unmet need as demonstrated by their performance on three key forward-looking metrics:
|The High Performers are leading the industry in the pivot to the patient:High Performers translate innovative new science into higher growth by excelling in demonstrating outcomes in specific patient groups to payers and carving out a share of stagnant health budgets. High Performers display the following attributes:
See our full results: Accenture Research Note: Biopharmaceutical High Performance Business Study—2013 Update